KRKA: Krka receives new S&P Global CSA Score

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No

/

2025

Date of issue:

2025-12-04

Short name of the issuer

KRKA

Subject

Krka receives new S&P Global CSA Score

Official market - legal basis

Art. 17 ust. 1 MAR

Unofficial market - legal basis

Contents of the report:

Based on the provisions of Article 26 of the Ljubljana Stock Exchange Rules, Article 158 of the Market in Financial Instruments Act, and Article 17 of Regulation (EU) No 596/2014, Krka, d. d., Novo mesto (hereinafter: Krka) discloses information regarding the acquisition of the S&P Global CSA Score.

On 3 December 2025, Krka scored 55 (out of 100) in the 2025 S&P Global Corporate Sustainability Assessment. Krka also obtained a modelled S&P Global ESG Score of 56 (out of 100).

The received independent score reaffirms the outlined direction of the Krka Group’s sustainable management practices and ESG governance, where we prioritize our social responsibility and care for the health and well-being of patients. We provide them with access to high-quality, safe, and effective medicines produced in accordance with the highest standards of good manufacturing practice. In this process, we place significant emphasis on environmental protection and reducing our environmental impact. In the governance of the Krka Group, we adhere to the highest standards of business ethics, integrity, and transparent operations.

This year, within the Krka Group Development Strategy until 2030, under the three strategic pillars, we have further outlined our commitment to providing uninterrupted access to medicines, developing innovative generic medicines for the treatment of chronic diseases, and value creation so that the positive impacts of our operations reach all Krka stakeholders. In this way, we fulfill Krka’s mission of Living a Healthy Life.

The received score serves as both an encouragement and a commitment to further improve the sustainability practices in the Krka Group.

This announcement will be published on the company’s website (www.krka.biz) starting from 4 December 2025, for a minimum period of 5 years.

Annexes

File

Description

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification

of the WSE in Warsow)

8501

Nove Mesto

(post code)

(city)

Smarjeska

(street)

(number)

+386 7 331 21 11

+386 7 332 15 37

(phone number)

(fax)

(e-mail)

(web site)

nie dotyczy

(NIP)

(REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

2025-12-04

Jože Colarič

President of the Management Board and CEO